Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 19/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697655 | 1.00 | RIPK2 (1.00) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14706917 | 0.96 | RIPK2 (0.92) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14706920 | 0.93 | RIPK2 (0.87) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14706913 | 0.91 | RIPK2 (0.84) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14697945 | 0.91 | RIPK2 (0.84) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14706943 | 0.91 | RIPK2 (0.84) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL25771943 | 0.91 | RIPK2 (0.84) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL20170695 | 0.91 | RIPK2 (0.83) | RIPK2GAKNOD2RIPK3 | |
| Hydrochloric Acid SCHEMBL25244211 | 0.90 | RIPK2 (0.82) | RIPK2GAKNOD2RIPK3 | |
| SCHEMBL14698021 | 0.90 | RIPK2 (0.82) | RIPK2GAKNOD2RIPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250230505-A1 | METHODS OF TREATING REFRACTORY INFLAMMATORY DISEASE USING TRANSCRIPTOMIC AND GENETIC RISK SIGNATURES | CEDARS-SINAI MEDICAL CENTER | 2025-07-17 | — | — | US | disclosed |
| US-12264368-B2 | Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures | CEDARS-SINAI MEDICAL CENTER (US) | 2025-04-01 | — | — | US | disclosed |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220273665-A1 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-09-01 | — | — | US | disclosed |
| CN-114375339-A | TL1A patient selection method, system and device | 普罗米修斯生物科学公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3969621-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | Prometheus Biosciences, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | RIPK2 4403/4885GAK 4623/4885NOD2 4679/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | RIPK2 4403/4885GAK 4623/4885NOD2 4679/4885 |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | RIPK2 4153/4885GAK 4750/4885NOD2 1888/4885 |
| US-20220273665-A1 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2 | RIPK2, RIPK1, RIPK4 | RIPK2 1/4885GAK 639/4885NOD2 11/4885 |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | DNASE1L3, TLL1, RNASE1 | RIPK2 4381/4885GAK 4325/4885NOD2 2839/4885 |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | TLL1, TSG101, DNASE1L3 | RIPK2 4153/4885GAK 4750/4885NOD2 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.